Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial.

Hdl Handle:
http://hdl.handle.net/10147/559134
Title:
Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial.
Authors:
Jones, Kelsey D J; Ali, Rehema; Khasira, Maureen A; Odera, Dennis; West, Annette L; Koster, Grielof; Akomo, Peter; Talbert, Alison W A; Goss, Victoria M; Ngari, Moses; Thitiri, Johnstone; Ndoro, Said; Knight, Miguel A Garcia; Omollo, Kenneth; Ndungu, Anne; Mulongo, Musa M; Bahwere, Paluku; Fegan, Greg; Warner, John O; Postle, Anthony D; Collins, Steve; Calder, Philip C; Berkley, James A
Citation:
Ready-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial. 2015, 13:93 BMC Med
Publisher:
BioMed Central
Journal:
BMC medicine
Issue Date:
2015
URI:
http://hdl.handle.net/10147/559134
DOI:
10.1186/s12916-015-0315-6
PubMed ID:
25902844
Abstract:
Ready-to-use therapeutic foods (RUTF) are lipid-based pastes widely used in the treatment of acute malnutrition. Current specifications for RUTF permit a high n-6 polyunsaturated fatty acid (PUFA) content and low n-3 PUFA, with no stipulated requirements for preformed long-chain n-3 PUFA. The objective of this study was to develop an RUTF with elevated short-chain n-3 PUFA and measure its impact, with and without fish oil supplementation, on children's PUFA status during treatment of severe acute malnutrition.; This randomized controlled trial in children with severe acute malnutrition in rural Kenya included 60 children aged 6 to 50 months who were randomized to receive i) RUTF with standard composition; ii) RUTF with elevated short chain n-3 PUFA; or iii) RUTF with elevated short chain n-3 PUFA plus fish oil capsules. Participants were followed-up for 3 months. The primary outcome was erythrocyte PUFA composition.; Erythrocyte docosahexaenoic acid (DHA) content declined from baseline in the two arms not receiving fish oil. Erythrocyte long-chain n-3 PUFA content following treatment was significantly higher for participants in the arm receiving fish oil than for those in the arms receiving RUTF with elevated short chain n-3 PUFA or standard RUTF alone: 3 months after enrollment, DHA content was 6.3% (interquartile range 6.0-7.3), 4.5% (3.9-4.9), and 3.9% (2.4-5.7) of total erythrocyte fatty acids (P <0.001), respectively, while eicosapentaenoic acid (EPA) content was 2.0% (1.5-2.6), 0.7% (0.6-0.8), and 0.4% (0.3-0.5) (P <0.001). RUTF with elevated short chain n-3 PUFA and fish oil capsules were acceptable to participants and carers, and there were no significant differences in safety outcomes.; PUFA requirements of children with SAM are not met by current formulations of RUTF, or by an RUTF with elevated short-chain n-3 PUFA without additional preformed long-chain n-3 PUFA. Clinical and growth implications of revised formulations need to be addressed in large clinical trials.; Clinicaltrials.gov NCT01593969. Registered 4 May 2012.
Item Type:
Article
Language:
en
Keywords:
NUTRITION; FOOD; PUBLIC HEALTH; CHILD
Local subject classification:
MALNUTRITION
ISSN:
1741-7015
Sponsors:
Funder: This study was funded by a grant from The Bill and Melinda Gates Foundation through the Grand Challenges Explorations initiative (OPP1046183) and by The Wellcome Trust via Fellowships to KDJJ (092088) and JAB (083579), which include salary support.

Full metadata record

DC FieldValue Language
dc.contributor.authorJones, Kelsey D Jen
dc.contributor.authorAli, Rehemaen
dc.contributor.authorKhasira, Maureen Aen
dc.contributor.authorOdera, Dennisen
dc.contributor.authorWest, Annette Len
dc.contributor.authorKoster, Grielofen
dc.contributor.authorAkomo, Peteren
dc.contributor.authorTalbert, Alison W Aen
dc.contributor.authorGoss, Victoria Men
dc.contributor.authorNgari, Mosesen
dc.contributor.authorThitiri, Johnstoneen
dc.contributor.authorNdoro, Saiden
dc.contributor.authorKnight, Miguel A Garciaen
dc.contributor.authorOmollo, Kennethen
dc.contributor.authorNdungu, Anneen
dc.contributor.authorMulongo, Musa Men
dc.contributor.authorBahwere, Palukuen
dc.contributor.authorFegan, Gregen
dc.contributor.authorWarner, John Oen
dc.contributor.authorPostle, Anthony Den
dc.contributor.authorCollins, Steveen
dc.contributor.authorCalder, Philip Cen
dc.contributor.authorBerkley, James Aen
dc.date.accessioned2015-07-07T10:46:14Zen
dc.date.available2015-07-07T10:46:14Zen
dc.date.issued2015en
dc.identifier.citationReady-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial. 2015, 13:93 BMC Meden
dc.identifier.issn1741-7015en
dc.identifier.pmid25902844en
dc.identifier.doi10.1186/s12916-015-0315-6en
dc.identifier.urihttp://hdl.handle.net/10147/559134en
dc.description.abstractReady-to-use therapeutic foods (RUTF) are lipid-based pastes widely used in the treatment of acute malnutrition. Current specifications for RUTF permit a high n-6 polyunsaturated fatty acid (PUFA) content and low n-3 PUFA, with no stipulated requirements for preformed long-chain n-3 PUFA. The objective of this study was to develop an RUTF with elevated short-chain n-3 PUFA and measure its impact, with and without fish oil supplementation, on children's PUFA status during treatment of severe acute malnutrition.en
dc.description.abstractThis randomized controlled trial in children with severe acute malnutrition in rural Kenya included 60 children aged 6 to 50 months who were randomized to receive i) RUTF with standard composition; ii) RUTF with elevated short chain n-3 PUFA; or iii) RUTF with elevated short chain n-3 PUFA plus fish oil capsules. Participants were followed-up for 3 months. The primary outcome was erythrocyte PUFA composition.en
dc.description.abstractErythrocyte docosahexaenoic acid (DHA) content declined from baseline in the two arms not receiving fish oil. Erythrocyte long-chain n-3 PUFA content following treatment was significantly higher for participants in the arm receiving fish oil than for those in the arms receiving RUTF with elevated short chain n-3 PUFA or standard RUTF alone: 3 months after enrollment, DHA content was 6.3% (interquartile range 6.0-7.3), 4.5% (3.9-4.9), and 3.9% (2.4-5.7) of total erythrocyte fatty acids (P <0.001), respectively, while eicosapentaenoic acid (EPA) content was 2.0% (1.5-2.6), 0.7% (0.6-0.8), and 0.4% (0.3-0.5) (P <0.001). RUTF with elevated short chain n-3 PUFA and fish oil capsules were acceptable to participants and carers, and there were no significant differences in safety outcomes.en
dc.description.abstractPUFA requirements of children with SAM are not met by current formulations of RUTF, or by an RUTF with elevated short-chain n-3 PUFA without additional preformed long-chain n-3 PUFA. Clinical and growth implications of revised formulations need to be addressed in large clinical trials.en
dc.description.abstractClinicaltrials.gov NCT01593969. Registered 4 May 2012.en
dc.description.sponsorshipFunder: This study was funded by a grant from The Bill and Melinda Gates Foundation through the Grand Challenges Explorations initiative (OPP1046183) and by The Wellcome Trust via Fellowships to KDJJ (092088) and JAB (083579), which include salary support.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rightsArchived with thanks to BMC medicineen
dc.subjectNUTRITIONen
dc.subjectFOODen
dc.subjectPUBLIC HEALTHen
dc.subjectCHILDen
dc.subject.otherMALNUTRITIONen
dc.titleReady-to-use therapeutic food with elevated n-3 polyunsaturated fatty acid content, with or without fish oil, to treat severe acute malnutrition: a randomized controlled trial.en
dc.typeArticleen
dc.identifier.journalBMC medicineen
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.